Ian Read News
-
Pfizer Inc., the world’s biggest drugmaker, will analyze over the next eight months whether it will split itself into brand name and generics businesses, Chief Financial Officer Frank D’Amelio said.
-
Pfizer Inc.’s Ian Read was the highest-paid chief executive officer at a large pharmaceutical company last year, as U.S. top managers remained on average much better paid than their European counterparts.
-
Pfizer Inc. plans to keep its $3.2 billion-a-year consumer health business because the unit will be critical to selling prescription drugs that become over-the- counter products, Chief Executive Officer Ian Read said.
-
Pfizer Inc., the world’s largest drugmaker, may consider dividing its branded medicines and generic products units into separate businesses, Chief Executive Officer Ian Read said.
-
Pfizer Inc. Chief Executive Officer Ian Read said the company’s decision to sell or spin off its animal and nutritional health units hasn’t reached a conclusion.
-
Pfizer Inc., the world’s largest drugmaker, put in place the last piece of its plan to refocus the company on developing new drugs, announcing it would start the separation of its animal-health business this month.
-
Pfizer Inc. Chief Executive Officer Ian Read received a 44 percent raise in total compensation last year to $25 million in his new role as head of the world’s largest drugmaker, according to a regulatory filing.
-
Pfizer Inc.’s industry-leading profit margins and disposal of non-drug businesses still haven’t closed the valuation gap with rival drugmakers. No wonder its chief executive officer is contemplating a full breakup.
-
Pfizer Inc. Chief Executive Officer Ian Read said he is reviewing the possible sale or spinoff of four divisions with $18.3 billion in annual revenue, led by the company’s third-biggest unit, established products.
-
Pfizer Inc.’s four business units may be combined into two, a top company official said, triggering speculation by analysts that the world’s biggest drugmaker is preparing to split in half.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page